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Objective: Patients with medically unexplained syndromes (MUS) often do not receive
appropriate healthcare. A critical time for effective healthcare is the inception of MUS. The
current study examined data from a prospective longitudinal study of Operation Enduring
Freedom/Operation Iraqi Freedom (OEF/OIF) veterans to understand the relationship of
increasing physical symptom burden to healthcare utilization.

Methods: Data was examined from a prospective study of OEF/OIF veterans assessed before
and one year after deployment (n=335). Physical symptom burden was measured with the
Patient Health Questionnaire (PHQ-15). Analyses were conducted with polynomial regression
and response surface analysis (RSA).

Results: Increases in physical symptom burden predicted greater healthcare utilization one year
after deployment: primary care practitioner (slope = -0.26, F=4.07, p=0.04), specialist (slope = .43, t=8.67, p=0.003), allied health therapy (e.g., physical therapy) (slope = -.41, t=5.71, p=0.02)
and mental health (slope = -.32, F=4.04, p=0.05). There were no significant difference in
utilization between those with consistently high levels and those with increases in physical
symptom burden.

Conclusion: This is the first prospective study to examine, and show, a relationship between
onset of clinically significant physical symptoms and greater healthcare utilization. Our data
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suggest that patients with increasing physical symptom burden have the same level of
healthcare as patients with chronic physical symptom burden. Needed next steps are to better
understand the quality of care at inception and determine how to intervene so that
recommended approaches to care are provided from the onset.
Keywords: Medically unexplained symptoms; healthcare utilization; care seeking; veterans;
deployment
An estimated 20% of primary care patients present with medically unexplained
syndromes or chronic symptom disorders (e.g., fibromyalgia, chronic fatigue syndrome)(1-5).
We use the term MUS as umbrella term to refer to conditions defined by multiple chronic
physical symptoms not better defined by another disorder; for a discussion of terminology
around MUS see (2, 6-9). Despite the name, MUS can be partially explained by a complex
interaction of physiological and psychological factors (4). MUS causes disability that is as
severe, or worse than, the disability of medically known conditions (e.g., cancer (10, 11)).
Further exacerbating the burden of MUS, patients with MUS often do not receive
appropriate healthcare. They have up to double the annual healthcare costs and utilization as
compared to patients without MUS (12). This healthcare is typically focused on trying to identify
the cause of the symptoms (13-17) leading to extensive diagnostic testing, hospitalizations,
inappropriate prescription of opioids (12-19) and care that is not patient-centered (20, 21). In
contrast, recommended approaches to care for patients with MUS focus on patient-centered
management of symptoms including: (1) a primary care provider evaluating the symptoms; (2)
regular visits with the primary care provider to reduce emergency and unnecessary care; and
(3) use of non-pharmaceutical, evidence-based treatments such as cognitive behavioral therapy
as a first line approach (22-30).
Considering the vicious cycle of symptom occurrence, inactivity, deconditioning, and
then worsening of symptoms and disability, a critical time for effective healthcare is at the
inception of MUS (31, 32). Despite this, no study has followed patients at the development of
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MUS to understand when healthcare utilization increases and what types of healthcare are
received at the onset. One reason for this knowledge gap is that it is difficult to identify who will
develop MUS (32). Combat exposure is, however, a known risk factor for developing MUS and
an estimated 30% of combat veterans will develop chronic MUS (33-35). We used data from an
existing study which assessed combat veterans prospectively from before to after deployment to
help us understand the frequency and type of health care utilization that occurs early in the
development of MUS.
While no study has prospectively looked at the relationship between onset of MUS and
healthcare utilization, there are reasons to hypothesize that healthcare utilization increases
immediately. Cross-sectional evidence finds a linear relationship between physical symptom
burden and greater healthcare utilization (12). Studies of the development of MUS recruit
patients using healthcare, suggesting that patients are seeking healthcare at the onset (14, 36,
37). Thus, our primary hypothesis is that there will be an association between increases in
physical symptom burden (from before to one year after deployment) and greater healthcare
utilization one year after deployment.
Increases in healthcare utilization may continue to increase over the duration of MUS.
Two prospective studies of patients with long-standing MUS found healthcare utilization
increased over time (38, 39). Further, a cross-sectional study of unexplained symptoms near the
onset of symptoms, found a relationship between greater duration and increased healthcare
utilization (40). Thus, our second hypothesis is that healthcare utilization increases with duration
of MUS. Specifically, veterans who report consistently high physical symptom burden (before
and after deployment) will report more healthcare utilization one year after deployment as
compared to veterans who reported an increase in physical symptom burden (new onset MUS).
To test these hypotheses, we used data from a prospective study of Operation Enduring
Freedom and Operation Iraqi Freedom soldiers assessed before and one year after
deployment. Physical symptom burden was measured with the Patient Health Questionnaire
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(PHQ-15), which has been used to screen for clinically significant levels of MUS [35]. Analyses
were conducted with polynomial regression and response surface analysis (RSA) which allowed
us to test the relationships in three dimensions and assess the influence of differing degrees of
change in symptom burden on healthcare utilization.
Methods
Participants
The HEROES project recruited Army National Guard and/or Reserve soldiers prior to
deployment to Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) from 20052008. Soldiers were approached during their standard preparation for deployment (for
description see (35, 41-43)). Soldiers between 18 and 60 were invited to participate. Based on
their influence on physical symptoms, exclusion criteria included (a) self-reported bipolar
disorder, major depression, or schizophrenia, (b) high blood pressure, (c) certain medication, or
(d) pregnancy. At the start of the study, 795 participants were eligible; 28 soldiers were
excluded from analysis because they (a) ultimately were not deployed, (b) were officers, or (c)
were killed in action.
Procedure
All study materials and procedures were reviewed by relevant institutional review boards
and research development committees. Responses to questionnaires were collected across
four phases: (1) before deployment, (2) immediately upon return from deployment, (3) threemonths after deployment, and (4) one-year after deployment. Before deployment and
immediately after deployment, questionnaires were administered in-person on base or through
the mail. Questionnaires were administered and collected through mail for the other phases.
The current data analysis was from the before deployment (n=767) and one year after
deployment (n=336) time points.
Measures
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Patient Health Questionnaire-15. Participants completed the PHQ-15 which asks how
burdened they were by physical symptoms over the past fourteen days. Each item was
measured on a scale from 0 = not bothered at all to 2 = bothered a lot. Burden was assessed
using established threshold: above 15 was high, 10 to 14 was medium, 5 to 9 was low, and 0 to
4 was no/mild (44). We used the pre-determined physical symptom cut-offs as this allows
interpretation between clinically significant (MUS; medium and high) and clinically nonsignificant (no-MUS; no/mild and low) levels of physical symptom burden and reduced the
influence of outliers in our three dimensional graphs. The PHQ-15 is a screening instrument for
MUS; the measure does not distinguish between medically explained and unexplained
symptoms. The PHQ-15 had an internal consistency of α=.75 before deployment and α=.69 one
year after deployment in our sample.
Healthcare Utilization. Healthcare utilization questions were adapted from the National
Health Interview Survey (45, 46). Items asked about healthcare utilization in the past year
including primary care practitioner, specialty care, allied health therapy (e.g., physical therapy,
occupational therapy) and mental health. Before deployment, veterans were asked if they had
seen any specialist. At one year after deployment, veterans were asked how many times they
had seen a gastroenterologist, pulmonologist, rheumatologist, neurologist or other specialist;
these items were added together for a total specialist score. Before deployment, the utilization
questions asked if the patient had received each type of care (yes/no) and there was one
question that asked how many medical appointments they had in the past year. At one year
after deployment, veterans were asked if they had received each type of care and how many
times they had received each type of care in the past year. To address the positive skew of the
count items, after data collection these were transformed into a Likert scale consistent with the
National Health Interview Survey (0, 1, 2-3, 4-9, 10 and above visits).

Analysis
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Paired t-tests and McNemar Related-Samples Test were conducted to examine if
physical symptoms and healthcare utilization increased from before to after deployment, a
premise of our first hypothesis. A MANOVA was used to determine the cross-sectional
relationship between level of physical symptom burden at one year after deployment and each
of the four types of healthcare utilization.
Hypothesis 1: Increases in physical symptom burden (from before to one year
after deployment) would be related to greater healthcare utilization one year after
deployment.
Polynomial regression and response surface analysis (RSA) (47-49) were used to
examine if changes in physical symptom burden were related to healthcare utilization at one
year after deployment. The advantage of polynomial regression and RSA is that the
relationships are represented in three dimensions as can be seen in Figure 1 (48-51). This
allows us to tell the influence of differing levels of change and different direction of change in
symptom burden on healthcare utilization, for different starting values of symptom burden.
These nuances would not be possible if one were to test a difference-score between before and
after deployment physical symptom burden as a single predictor or if one were to create artificial
groups of veterans based on their change in symptom burden.
There are multiple steps to a polynomial regression analysis. In the first step, a linear
polynomial model is created with centered independent variables (X=before deployment
symptom burden and Y=after deployment symptom burden) that predict the outcome (Z=after
deployment healthcare utilization). For the second step, a quadratic polynomial model is
created. This model includes X2, XY, and Y2. The third step a polynomial model is constructed,
including X3, XY2, X2Y, Y3. When the cubic model (third step) is significant, a quartic model
(fourth step) is tested. The interpreted step is the last step where the change in R2 is statistically
significant (see Table 4.
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The polynomial and RSA analyses for this study controlled for frequency of receiving any
healthcare before deployment. The three dimensional graph can only have three variables. To
allow us to control for healthcare utilization before deployment, we regressed the control
variable (healthcare utilization before deployment) on each dependent variable and saved the
unstandardized residual. We then conducted the polynomial regression analysis using the each
of these unstandardized residuals as the dependent variables. The regression coefficients of the
final model were used to conduct the RSA analyses (48, 49, 51).
Figure 1 shows the RSA. The Z-axis (vertical) is the dependent variable, frequency of
health care utilization, the X-axis is before deployment symptom burden and the Y-axis is after
deployment symptom burden. A visual inspection of the graph shows the level of healthcare
utilization at different combinations of before and after deployment symptom burden. To
interpret the graph, it is useful to look at the surface along the line of congruence, which is when
X=Y or when before symptoms are the same as after symptoms (solid perpendicular line in
Figure 1a); and the surface along the line of incongruence, which is when X+Y=0 or before and
after deployment symptoms are different from each other (dashed perpendicular line in Figure
1a). The line of incongruence is conceptually the same as testing the difference score (after
minus before deployment symptom burden) as a predictor of the outcome. Descriptions of
polynomial regression and RSA can be found in (48-51).
For Hypothesis 1, we were interested in the slope of the surface along the line of
incongruence. The slope of this line tells us: (a) if healthcare utilization was greater when
symptom burden increased, (b) if healthcare utilization was greater when symptom burden
decreased, or (c) if there was no relationship between change in symptom burden and
healthcare utilization. We hypothesized a negative slope, which would indicate that healthcare
utilization was greater when symptom burden increased from before to after deployment. We
also examined if there was curvature (if quadratic) of the surface along the line of incongruence.
This curvature would indicate that the relationship between change in symptoms and healthcare
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utilization was not linear, meaning that the association between change in symptoms and
healthcare utilization was different at the ends of the line of incongruence as compared to the
center of the line of incongruence.
We next examined the slope of the surface along the line of congruence to understand if
healthcare utilization was greater when before and after symptom burden were both high as
compared to when both were low. Finally, we examined if there was curvature (if quadratic) of
the surface along the line of congruence which would indicate that the relationship of
consistently high or low symptom burden and healthcare utilization was not linear, meaning that
the relationship between symptoms and healthcare utilization was different when symptoms
were consistently high as compared to constantly low.
Hypothesis 2: Veterans who reported consistently high physical symptom burden
both before and after deployment would report more healthcare utilization one year after
deployment as compared to veterans who reported an increase in physical symptom
burden.
This was first determined by visual examination of the three dimensional graph (See
Figure 1a-1d). We next compared the healthcare utilization of veterans who had high levels of
physical symptoms at before and after deployment (high/high; defined as medium to high
physical symptom burden at both times) to veterans who had low physical symptoms at before
and after deployment (low/low; defined as no/mild to low physical symptom burden at both
times) to veterans who reported low symptoms (defined as no/mild to low physical symptom
burden) at before deployment to high (defined as medium to high physical symptom burden)
one year after deployment (low/high). A MANCOVA was conducted to determine if there were
significant differences between the groups in each of the four types of healthcare utilization
controlling for before deployment levels of healthcare utilization. Unlike the polynomial
regression, Veterans were split into groups (high/high, low/low, low/high) for a direct comparison
of the average levels of utilization between these groups. The ANCOVAs report the effect size
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eta-squared which is the proportion of variance for which the dependent variable accounted and
Pillai’s Trace which is a test statistic.
Results
The majority of participants were male (n=288, 86%), white (n=277, 82.4%) with a mean
age of 30.2 (SD=9.1). Participants who completed the one-year assessment post-deployment
(compared to those who did not) were older and more likely to be male, and trend towards
reporting more healthcare utilization at baseline (1.1 vs. .9; p=.07); there were no differences in
physical symptom burden.
There was an average increase in physical symptom burden from before to one year
after deployment (Table 1; t=8.13, p<.001). There was also an average increase in healthcare
utilization (Table 2; All four of the McNemar Related-Samples Test, p<.05).
Consistent with previous research, preliminary analysis using MANOVA showed a crosssectional relationship between greater physical symptom burden one year after deployment and
greater healthcare utilization (primary care practitioner, specialist, therapy, mental health care)
one year after deployment (Table 3; Pillai’s Trace=.18, F(12, 939)=5.12, p<.001, Eta
Squared=.06). The separate univariate ANOVAs showed a significant cross-sectional
relationship between greater level of physical symptom burden and more frequent visits to a
primary care (F(3, 314)=15.6, p<.001, Eta Squared=.13), specialist (F(3, 314)=6.95, p<.001, Eta
Squared=.06), allied health therapist (F(3, 314)=3.57, p<.01, Eta Squared=.03) and mental
health services (F(3, 314)=12.57, p<.001, Eta Squared=.11).

Hypothesis 1: Increases in physical symptom burden (from before to one year
after deployment) would be related to greater healthcare utilization one year after
deployment.
Primary Care Practitioner. The linear model was the final model of the polynomial
regression analysis (R2 change =0.05, p<.001; Figure 1a, Table 4) which is interpreted as
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follows. In support of the hypothesis, there was greater utilization of a primary care practitioner
when physical symptom burden increased (from before to after deployment) as compared to
when physical symptom burden decreased; the slope of the surface along the line of
incongruence was significant and negative (slope = -0.26, F=4.07, p=0.04). There was also
greater utilization of a primary care practitioner when physical symptoms burden was
consistently high as compared to when physical symptom burden was consistently low; the
slope of the surface along the line of congruence (when physical symptoms were equal at
before and after deployment) was positive and significantly greater than zero (slope = 0.25,
F=7.97, p<.01).
Specialist Care. The cubic model was the final model (R2 change=0.06, p< .001; Table
4) which is interpreted as follows. There was greater utilization of a specialist when physical
symptom burden increased (from before to after deployment) compared to when physical
symptom burden decreased; the slope of the surface along the line of incongruence was
significant and negative (slope=-.43, t=8.67, p=0.003). Greater increases in physical symptom
burden (towards the end of the line of incongruence) were associated with much greater
utilization of specialist care; this is indicated by a significant curvature of the surface along the
line of incongruence (curvature=0.71, F=13.86, p<.001). Similarly, when there were high levels
of physical symptom burden at both before and after deployment (line of congruence) there was
much greater utilization of specialist care; this is indicated by a positive and significant curvature
of the surface along the line of congruence (curvature=0.32, F=10.14, p=0.002). The
interpretation of the cubic component of the model is the same as described above, except that,
as indicated in the Figure 1b, utilization was lowest in the middle of the surface (for closer-toaverage levels of before and after symptom burden) than at the extremes.
Allied Health Therapy. The quadratic model was the final model of the polynomial
regression analysis for allied health therapy utilization (R2 change =0.024, p=.04; Figure 1c,
Table 4) which is interpreted as follows. There was greater utilization of a therapist (e.g.,
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physical therapist) when physical symptom burden increased (from before to after deployment)
compared to when physical symptom burden decreased (see Figure 1c); the slope of the
surface along the line of incongruence was significant and negative (slope=-.41, t=5.71,
p=0.02). Greater increases in physical symptom burden was associated with much greater
allied health utilization as compared to lower increases in physical symptom burden which were
associated with lower allied health utilization; this is indicated by significant curvature of the
surface along the line of incongruence (curvature=0.52, F=5.40, p=0.021). Finally, those with
high levels of symptom burden at before and after deployment used therapy significantly more
than those with low levels of symptom burden at before and after deployment; the slope of the
surface along the line of congruence (when physical symptom burden before and after
deployment were equal) was positive and significantly greater than zero (slope=0.26, F=4.42,
p=0.04).
Mental Health. The polynomial regression analysis for mental health utilization showed
the linear model was the final model (R2 change =0.096, p<.001; Figure 1d, Table 4), which is
interpreted as follows. There was greater utilization of mental health when physical symptom
burden increased (from before to after deployment) as compared to when physical symptom
burden decreased; the slope of the surface along the line of incongruence was significant and
negative (slope=-.32, F=4.04, p=0.05). Those with high level of symptom burden at before and
after deployment used mental health services significantly more than those with low level of
symptom burden at before and after deployment; the slope of the surface along the line of
congruence (when physical symptom burden before and after deployment were equal) was
positive and significantly greater than zero (slope=0.49, F=20.86, p<.001).
Hypothesis 2: Veterans who report greater physical symptom burden both before and
after deployment, will report more healthcare utilization one year after deployment
compared to veterans who report an increase in physical symptom burden.
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Visual inspection of the graphs of specialty care, allied health therapy and mental health
(Figure 1a-d) suggest that for veterans with the highest levels of physical symptom burden,
healthcare utilization may be higher for those with consistently high levels of physical symptom
burden as compared to those who experience an increase in physical symptom burden. This is
consistent with hypothesis two.
We conducted a MANCOVA to further test this hypothesis, which did not support
hypothesis two (Table 5). As described below, while the overall model was significant, there
were no main effects differences in healthcare utilization between veterans who had an increase
in physical symptom burden as compared to veterans with consistently high physical symptom
burden.
To conduct the MANCOVA, we split veterans into three groups, veterans who had
consistently high levels of physical symptom burden (high/high) and veterans who increased
their physical symptom burden (low/high) and veterans who had consistently low levels of
physical symptom burden (low/low). The overall MANCOVA found the level of physical symptom
burden change (low/low, low/high, high/high) was significantly related to healthcare utilization
one year after deployment (Table 5 Pillai’s Trace=.10, F(8, 616)=3.91, p<.001, Eta
Squared=.05). There was an association between physical symptom burden change (low/low,
low/high, high/high) and greater utilization for primary care practitioner (F(2, 314)=4.09, p=.02,
Eta Squared=.03), specialty physician (F(2, 314)=6.62, p<.01, Eta Squared=.04), allied health
therapy (e.g., physical therapy; F(2, 314)=5.74, p<.01, Eta Squared=.04) and mental health
services (F(2, 314)=10.49, p<.001, Eta Squared=.06).
Comparing the main effects, there were no significant differences between veterans with
low/high or high/high levels of physical symptoms burden, which was not supportive of
hypothesis two. Veterans with low/low physical symptom burden had significantly less
healthcare utilization as compared to veterans with low/high or high/high levels of physical
symptom burden.
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Discussion
The onset of medically unexplained physical syndromes (MUS) is a critical time for
effective healthcare. Early intervention can lead to management approaches that improve
disability and symptoms in the long-term. Despite this, no study has observed individuals from
before to after the development of physical symptoms to understand early healthcare utilization.
The current study examined data from a prospective longitudinal study of Operation Enduring
Freedom/Operation Iraqi Freedom (OEF/OIF) veterans to understand the relationship of
increasing physical symptom burden to healthcare utilization.
A premise of our hypotheses was that veterans would have significant increases in
physical symptom burden from before to after deployment; this was supported. Before
deployment, 14% of veterans reported levels of physical symptoms burden that was likely
clinically significant. After deployment, this number rose to 33%. This increase is consistent with
previous studies which find approximately 30% of combat veterans report clinically significant
MUS (33, 35, 52). This study captured MUS with the PHQ-15 where ‘medium’ to ‘high’ levels of
MUS were considered clinically significant.
Increases in physical symptom burden predicted healthcare utilization one year after
deployment. This was true for all four types of healthcare utilization: primary care, specialist,
allied health therapy (e.g., physical therapy) and mental health. To our knowledge this is the first
study to show a relationship between onset of physical symptom burden and greater utilization
of multiple types of healthcare. Importantly, all these analyses controlled for frequency of
healthcare utilization before deployment; controlling for baseline levels of utilization controlled
for the variance accounted for by the individual tendency to seek healthcare. This suggests the
results are not due to some veterans being simply more likely to seek healthcare.
Veterans with high levels of physical symptom burden after deployment show patterns of
utilization that is both consistent and inconsistent with current recommendations. With the
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Veterans Health Administration’s (VHA’s) move to primary care homes, primary care
practitioners are more than ever expected to organize care in collaboration with a team of
healthcare professionals (e.g., psychologists, physical therapists). In this setting, veterans with
MUS would ideally receive more frequent care from their primary care, mental health and allied
health providers, who deliver treatments with the strongest evidence (e.g., cognitive behavioral
therapy). This study demonstrates guideline congruent increases in primary, mental health, and
allied health care.
Clinical practice guidelines also suggest that specialist care be saved for exclusionary
testing or second opinions. In this study, however, the slopes of incongruence (relationships
between increasing physical symptoms and healthcare utilization) were strongest for specialty
care and allied health therapy (.43 and .42 respectively) and lower for primary care practitioner
and mental health care (.25 and .32 respectively). The graphs for specialty and allied health
therapy also were more complex (i.e., curvature) as compared to primary care and mental
health care (i.e., linear) which should be explored in future studies. The relationship between
greater specialist care and increases in physical symptom burden suggests that veterans with
high levels of physical symptom burden are receiving a significant portion of their care from
specialists, which is inconsistent with recommendations. Further, while it is encouraging that
veterans are using mental and allied health care, they made, on average, one visit a year which
is not typically an effective dose of this care.

The hypothesis that veterans with consistent high levels of physical symptom burden
would have greater utilization as compared to veterans who are first developing high levels of
physical symptom burden was not supported with the MANCOVA. Patients with MUS receive up
to double the levels of healthcare utilization and costs as compared to patients with known
medical conditions (12, 18, 19). Our findings suggest that inappropriate healthcare could be
occurring from the start. It is also possible that our comparison group of veterans with consistent
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levels of high physical symptoms is not representative of patients with chronic MUS. Veterans
who had high levels of physical symptoms before deployment may be healthier than civilians
their age with MUS, as they were healthy enough to deploy and their healthcare utilization was
not extremely high (Table 5). Alternatively, they may have been not healthier than civilians with
chronic MUS, but deployed out of an obligation to their units.
While our MANCOVA results did not show significant difference between those with
consistently high levels of physical symptoms (n=83) and those with increases in physical
symptom burden (n=29), the graphs suggest that there may be non-significant differences for
veterans with the most severe physical symptoms. As there were only 13 veterans with the
highest levels of physical symptom burden after deployment we were not able to test this
statistically. Future research with a larger population is needed to test this possibility.
A limitation of our study was not having a physician diagnosis of MUS. The PHQ-15 is a
common screening measure of MUS. The PHQ-15 does not differentiate between medically
explained and unexplained symptoms. This is consistent with current evidence that greater
symptom burden is impairing regardless of the cause (2, 53) and has led to calls to change the
term from MUS to physical symptom disorder or chronic multisymptom illness, among others (6,
8, 54). As there is not yet consensus on the best terminology, we used MUS to be consistent
with the current literature. Other terms (6, 8, 54), better reflect the actual phenomena and what
is captured by the PHQ-15, although are less frequently used in the literature. Regardless of
terminology, physician diagnosis would help us understand if these symptoms were clinically
relevant.
This study also did not capture the quality of care. It is unknown if veterans were
receiving appropriate treatments (e.g., Cognitive-Behavioral Therapy) or less appropriate
treatments (e.g., opioids). It is also unknown if veterans receive patient-centered care at the
onset of MUS. Qualitative research finds some providers think treating MUS is difficult, which
can lead to frustration with the patient (55).
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The use of a military sample is a strength and limitation. Because combat deployment is
a risk factor for developing MUS, observing soldiers before and after combat allowed us to
prospectively observe participants as they developed significant physical symptom burden.
Further, because MUS impacts 30% of combat veterans, this is an important population for
whom to improve the management of MUS. We do not, however, know the generalizability of
the results to a civilian population and the changes to mailing addresses and telephone
numbers that occur from before to after deployment contributed to our high attrition rate.
In summary, this is the first prospective study to examine, and show, a relationship
between onset of clinically significant physical symptoms (MUS) and greater healthcare
utilization. Our data also suggest that patients with new onset physical symptom burden have
the same levels of healthcare utilization as patients with chronic physical symptom burden.
Effective healthcare can improve the management of MUS and in the long-term reduce disability
and physical symptoms. Next steps are to better understand the quality of care at inception and
determine how to intervene so that recommended approaches to care are provided from the
start.
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Table 1: Number of participants with each level of physical symptom burden (measured with the
PHQ-15) before deployment and one year after deployment (n=336).

No/mild sx

No/mild sx

Low sx

Medium sx

High sx

Total Before

1 Yr After Deploy

1 Yr After Deploy

1 Yr After Deploy

1 Yr After Deploy

Deployment

88

45

24

14

171 (50.9%)

26

47

35

10

118 (35.1%)

3

15

14

9

41 (12.2%)

0

0

2

4

6 (1.8%)

117 (34.8%)

107 (31.8%)

75 (22.3%)

37 (11.0%)

Before Deploy
Low sx
Before Deploy
Medium sx
Before Deploy
High sx
Before Deploy
Total 1 Yr. After
Deploy
Deploy=Deployment, Sx=Symptoms, Yr=Year
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Table 2: Number endorsing healthcare utilization before deployment and one year after deployment
(n=318).
Before Deployment

One Year After Deploymenta

Primary Care

144 (44.0%)

217 (68.0%)

Specialist*

33 (10.1%)

100 (31.1%)

Allied Health

35 (10.6%)

82 (25.9%)

Mental Health

28 (8.5%)

113 (35.4%)

*Before deployment soldiers were asked if they had seen any specialist. At 1 year after deployment they
were asked how many times they had seen a gastrologist, pulmonologist, rheumatologist, neurologist or
other specialist, these items were added together for a total specialist score. aThere was an average
increase in healthcare utilization; a McNemar Related-Samples Test for each type of healthcare utilization
was significant, p<.05.
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Table 3: Cross-sectional relationship of Physical Symptoms to Healthcare Utilization one year
after deployment (% who self-reporting attending healthcare utilization; n=318).
No/Mild Sx.

Low Sx.

Medium Sx.

High Sx.

Primary care

60.7%

72.7%

73.3%

65.6%

Specialist

18.8%

35.4%

30.7%

62.5%

Allied Health

10.8%

33.0%

29.3%

46.9%

Mental Health

21.4%

36.4%

42.7%

62.5%

Sx.=symptoms
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Table 4: Polynomial regression analyses of differing degrees of change in physical symptoms
(from before to one year after deployment) predicting healthcare utilization one year after
deployment (n=315).a
Primary care

Specialist

Mental Health

Practitioner

Step 1

Healthcare utilization

Allied Health
Therapist

B (SE)

∆R2

B (SE)

∆R2

B (SE)

∆R2

B(SE)

∆R2

.14 (.06)*

.02*

.09 (.61)

.01

.06 (.08)

.00

.11 (.07)

.01

.13 (.06)*

.05*

.08 (.06)

.10*

.03 (.07)

.10*

.08 (.07)

.09*

(before)
Step 2

Healthcare utilization
(before)

Step 3

PHQ-15 (before)

-.00 (.09)

-.04 (.09)

.09 (.11)

.08 (.10)

PHQ-15 (after)

.26 (.07)*

.36 (.06)*

.41 (.08)*

.35 (.08)*

Healthcare utilization

.01

.06 (.06)

.05*

.02

.07 (.07)

.02*

(before)
PHQ-15 (before)

-.16 (.10)

-.07 (.12)

PHQ-15 (after)

.26 (.07)*

.33 (.09)*

PHQ-15 (before)2

.38 (.11)*

.38 (.13)*

PHQ-15(before)

-.20 (.09)*

-.18 (.11)

.14(.07)*

-.02 (.08)

*PHQ-15(after)
PHQ-15 (after)2
Step 4^
aThe

.02

.05*

.01

.02

regression coefficients are not directly interpretable but are used to calculate the lines of congruence
(when symptoms are the same at baseline and one year after deployment) and incongruence (when
symptoms are different at baseline and one year after deployment). The slopes and curvatures of these
calculated lines are in the results section, *p<.05, B=unstandardized regression weight, SE=standard
error, ∆R2=change in R2 for each step - the change is incremental and the total R2 increases with each
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step, before=before deployment, after=one year after deployment, PHQ-15=physical symptoms, ^Step 4
included step 1-3 variables, PHQ_15 (before)2 interaction with PHQ_15(after), PHQ_15 (after)2 interaction
with PHQ_15 (after), PHQ_15 (before)3 and PHQ_15 (after)3. The beta weights of Step 4 are not directly
interpretable and therefore not reported but are available upon request.

Table 5: Relationship of level of physical symptom change (from before to one year after
deployment) to frequency* of healthcare utilization one year after deployment; mean* (standard
error) (n=316).
Low/Low

Low/High

High/High

Primary care Practitioner

1.17 (.08)

1.56 (.13)a

1.52 (.21)a

Specialist

.49 (.08)

.88 (.12)a

1.13 (.21)a

Allied Health Therapy

.50 (.09)

.99 (.14)a

1.05 (.24)a

Mental Health

.66 (.10)

1.43 (.15)a

1.36 (.26)a

*=likert scale of number of visits in the past year where 0=0 visits, 1=1 visit and 2=2-3 visits, 3=4-9 visits,
and 4=10 or more visits, Low/Low= no/mild to low physical symptoms before deployment to no/mild to low
physical symptoms one year after deployment; Low/High=no/mild to low physical symptoms before
deployment to medium to high physical symptoms one year after deployment; High/High=Medium to high
physical symptoms before deployment to medium to high physical symptoms one year after deployment.
a= significant difference with low/low group.
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